Carbapenemase producing Klebsiella pneumoniae: implication on future therapeutic strategies

Carbapenemase-Producing Klebsiella pneumoniae Colonization and Infection in Solid Organ Transplant Recipients: A Single-Center, Retrospective Study

“…By contrast, the role of immunosuppressive therapy is unclear in this context. Our results do not allow any deduction about the role of immunosuppressive treatment in terms of the risk of MDR pathogen infections, which has not been confirmed by previous studies [26,27].…”

“…Sun et al reported that C/A significantly reduced short-term mortality among SOT recipients with CPE infections compared with salvage regimens [30]. Data in SOT per M/V and I/R, for now, are few, and we are waiting for further studies [27].…”

“…Recently, novel beta-lactams/beta-lactams inhibitors combinations such as ceftazidime/ avibactam (C/A), meropenem/vaborbactam (M/V) and imipenem/relebactam (I/R) significantly reduced mortality patients with carbapenem-resistant Enterobacteriaceae infections [27][28][29]. Notably, C/A is an intravenous combination of a third-generation cephalosporin with the non-β-lactam/β-lactamase inhibitor avibactam, with activity against ESBL-producing bacteria, P. aeruginosa, and KPC or OXA-48 carbapenemase-producing bacteria [28,29].…”

Direct Testing for KPC-Mediated Carbapenem Resistance from Blood Samples Using a T2 Magnetic Resonance Based Assay

“…However, important factors-including costs and laboratory personnel staffing-need to be considered when implementing rapid methods in laboratory diagnostic workflows [13]. Among carbapenemase-producing Enterobacterales, K. pneumoniae is a global public health menace, with KPC-producing K. pneumoniae being the most prevalent Gram-negative species identified in Italy and some other countries [21]. Novel agents such as ceftazidime/avibactam, meropenem/vaborbactam, and imipenem/cilastatin/relebactam are practical options to combat carbapenem-resistant infections [21].…”

“…Among carbapenemase-producing Enterobacterales, K. pneumoniae is a global public health menace, with KPC-producing K. pneumoniae being the most prevalent Gram-negative species identified in Italy and some other countries [21]. Novel agents such as ceftazidime/avibactam, meropenem/vaborbactam, and imipenem/cilastatin/relebactam are practical options to combat carbapenem-resistant infections [21]. Thus, rapid molecular tests-usually designed to identify a limited spectrum of microbial species and of antimicrobial resistance determinants-may be reasonably considered for guiding therapeutic decisions in settings where carbapenemases are the major driver of carbapenem resistance [13].…”